Results 161 to 170 of about 47,199,121 (367)

The work of the imperial cancer research fund [PDF]

, 1907
E. F. Bashford
openalex   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Migrants Living in the United Kingdom and Their Perceptions of Participation in Health Research: A Mixed-Methods Study. [PDF]

Health Expect
Gogoi M, Baggaley RF, Silva L, Lal Z, Reilly H, Modhwadia V, Pan D, Bird P, Nellums L, Pareek M.   +9 more
europepmc   +1 more source

April, 1 \u2013 in the aftermath of elections: some words about the parliamentary majority [PDF]

, 2002
Research, Update
core  

Retracted: Exploring Drug Targets in Isoprenoid Biosynthetic Pathway for Plasmodium falciparum

Biochemistry Research International, 2022
Biochemistry Research International
doaj   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Try to Look Again: A Phenomenological Study of Recognising Humanness in People Living With Advanced Dementia. [PDF]

Scand J Caring Sci
Bøgmose J, Olivares Bøgeskov B, Dening T, Martinsen B.   +3 more
europepmc   +1 more source

\uabFor our single Ukraine\ubb: hard pre-election blocking [PDF]

, 2001
Research, Update
core  

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Enduring the Unbearable-A Phenomenological Hermeneutical Study on Nurses' Lived Experiences of Stress During the COVID-19 Pandemic. [PDF]

Scand J Caring Sci
Carnesten H, von Heideken Wågert P, Wiklund Gustin L, Skoglund K, Andreae C.   +4 more
europepmc   +1 more source